Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes

British Journal of Pharmacology

Volumn , Issue , 2016, Pages 2165-2181

  Cowan, Elaine ^a   Burch, Kerry J ^a   Green, Brian D ^a   Grieve, David J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; LEPTIN; MAMMALIAN TARGET OF RAPAMYCIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; OBESTATIN; PROTEIN KINASE B; S6 KINASE; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADIPOCYTE; ADIPOSE TISSUE; APOPTOSIS; BLOOD PRESSURE REGULATION; BODY MASS; CARDIAC MUSCLE CELL; CARDIOVASCULAR FUNCTION; CELL SURVIVAL; DIABETES MELLITUS; DUODENUM; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; IMMUNOREACTIVITY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESISTANCE; INTESTINE CONTRACTION; INTESTINE MOTILITY; JEJUNUM; LIPID METABOLISM; METABOLIC REGULATION; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; PROTEIN SYNTHESIS; REVIEW; VASCULAR ENDOTHELIUM;

EID: 84976544141     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13502     Document Type: Review

References (197)

1. Agnew A, Calderwood D, Chevallier OP, Greer B, Grieve DJ, Green BD (2011). Chronic treatment with a stable obestatin analog significantly alters plasma triglyceride levels but fails to influence food intake; fluid intake; body weight; or body composition in rats. Peptides 32: 755–762.
2. Agnew AJ, Robinson E, McVicar CM, Harvey AP, Ali IH, Lindsay JE et al. (2012). The gastrointestinal peptide obestatin induces vascular relaxation via specific activation of endothelium-dependent NO signalling. Br J Pharmacol 166: 327–338.
3. Aktas B, Yilmaz Y, Eren F, Yonal O, Kurt R, Alahdab YO et al. (2011). Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism 60: 544–549.
4. Alen BO, Nieto L, Gurriaran-Rodriguez U, Mosteiro CS, Alvarez-Perez JC, Otero-Alen M et al. (2012). The NMR structure of human obestatin in membrane-like environments: insights into the structure–bioactivity relationship of obestatin. PLoS One 7: e45434.
5. Alexander SP, Cidlowski JA, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: nuclear hormone receptors. Br J Pharmacol 172: 5956–5978.
6. Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744–5869.
7. Alexander SP, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015c). The Concise Guide to PHARMACOLOGY 2015/16: enzymes. Br J Pharmacol 172: 6024–6109.
8. Alexander SP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015d). The Concise Guide to PHARMACOLOGY 2015/16: transporters. Br J Pharmacol 172: 6110–6202.
9. Alexandridis E, Zisimopoulos A, Liratzopoulos N, Katsos I, Manolas K, Kouklakis G (2009). Obestatin/ghrelin ratio: a new activity index in inflammatory bowel diseases. Inflamm Bowel Dis 15: 1557–1561.
10. Alloatti G, Arnoletti E, Bassino E, Penna C, Perrelli MG, Ghé C et al. (2010). Obestatin affords cardioprotection to the ischemic–reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes. Am J Physiol Heart Circ Physiol 299: H470–H481.
11. Anderwald-Stadler M, Krebs M, Promintzer M, Mandl M, Bischof MG, Nowotny P et al. (2007). Plasma obestatin is lower at fasting and not suppressed by insulin in insulin-resistant humans. Am J Physiol Endocrinol Metab 293: E1393–E1398.
12. Aragno M, Mastrocola R, Ghé C, Arnoletti E, Bassino E, Alloatti G et al. (2012). Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: underlying mechanisms. Cardiovasc Diabetol 11: 129.
13. Arrigo T, Gitto E, Ferraù V, Munafò C, Alibrandi A, Marseglia GL et al. (2012). Effect of weight reduction on leptin, total ghrelin and obestatin concentrations in prepubertal children. J Biol Regul Homeost Agents 26: S95–S103.
14. Ataka K, Inui A, Asakawa A, Kato I, Fujimiya M (2008). Obestatin inhibits motor activity in the antrum and duodenum in the fed state of conscious rats. Am J Physiol Gastrointest Liver Physiol 294: G1210–G1218.
15. Ayada C, Toru U, Genc O, Simsek H, Sahin S, Admis O et al. (2015). Serum levels of obestatin and adiponectin in patients with obstructive sleep apnea syndrome. Acta Physiol (Oxf) 215 : 90.Suppl S705
16. Aydin S, Ozkan Y, Erman F, Gurates B, Kilic N, Colak R et al. (2008). Presence of obestatin in breast milk: relationship among obestatin, ghrelin, and leptin in lactating women. Nutrition 24: 689–693.
17. Aygen B, Dogukan A, Dursun FE, Aydin S, Kilic N, Sahpaz F et al. (2009). Ghrelin and obestatin levels in end-stage renal disease. J Int Med Res 37: 757–765.
18. Bang AS, Soule SG, Yandle TG, Richards AM, Pemberton CJ (2007). Characterisation of proghrelin peptides in mammalian tissue and plasma. J Endocrinol 192: 313–323.
19. Baragli L, Grande C, Gesmundo I, Settanni F, Taliano M, Gallo D et al. (2013). Obestatin enhances in vitro generation of pancreatic islets through regulation of developmental pathways. PLoS One 8: e64374.
20. Bassil AK, Häglund Y, Brown J, Rudholm T, Hellström PM, Näslund E et al. (2007). Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract. Br J Pharmacol 150: 58–64.
21. Baykus Y, Gurates B, Aydin S, Celik H, Kavak B, Aksoy A et al. (2012). Changes in serum obestatin, preptin and ghrelins in patients with gestational diabetes mellitus. Clin Biochem 45: 198–202.
22. Beasley JM, Ange BA, Anderson CA, Miller Iii ER, Holbrook JT, Appel LJ (2009). Characteristics associated with fasting appetite hormones (obestatin, ghrelin, and leptin). Obesity (Silver Spring) 17: 349–354.
23. Bresciani E, Rapetti D, Donà F, Bulgarelli I, Tamiazzo L, Locatelli V et al. (2006). Obestatin inhibits feeding but does not modulate GH and corticosterone secretion in the rat. J Endocrinol Invest 29: RC16–RC18.
24. Brunetti L, Leone S, Orlando G, Recinella L, Ferrante C, Chiavaroli A et al. (2009). Effects of obestatin on feeding and body weight after standard or cafeteria diet in the rat. Peptides 30: 1323–1327.
25. Brunetti L, Di Nisio C, Recinella L, Orlando G, Ferrante C, Chiavaroli A et al. (2010). Obestatin inhibits dopamine release in rat hypothalamus. Eur J Pharmacol 641: 142–147.
26. Buescher AK, Buescher R, Hoyer PF (2010). Regulation of ghrelin, obestatin and adiponectin in pediatric patients with chronic renal insufficiency and after renal transplantation. Endocr Rev 31: P3–697.
27. Bugger H, Abel ED (2014). Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 57: 660–671.
28. Bukowczan J, Warzecha Z, Ceranowicz P, Kuśnierz-Cabala B, Tomaszewska R, Dembinski A (2015). Pretreatment with obestatin reduces the severity of ischemia/reperfusion-induced acute pancreatitis in rats. Eur J Pharmacol 760: 113–121.
29. Butler MG, Bittel DC (2007). Plasma obestatin and ghrelin levels in subjects with Prader–Willi syndrome. Am J Med Genet A 143: 415–421.
30. Cassoni P, Ghé C, Marrocco T, Tarabra E, Allia E, Catapano F et al. (2004). Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur J Endocrinol 150: 173–184.
31. Ceranowicz P, Warzecha Z, Dembinski A, Cieszkowski J, Dembinski M, Sendur R et al. (2009). Pretreatment with obestatin inhibits the development of cerulein-induced pancreatitis. J Physiol Pharmacol 60: 95–101.
32. Chen CY, Lee WJ, Chong K, Lee SD, Liao YD (2012a). Impact of intracerebroventricular obestatin on plasma acyl ghrelin, des-acyl ghrelin and nesfatin-1 levels, and on gastric emptying in rats. Mol Med Rep 6: 191–196.
33. Chen CY, Chien EJ, Chang FY, Lu CL, Luo JC, Lee SD (2008). Impacts of peripheral obestatin on colonic motility and secretion in conscious fed rats. Peptides 29: 1603–1608.
34. Chen CY, Doong ML, Li CP, Liaw WJ, Lee HF, Chang FY et al. (2010). A novel simultaneous measurement method to assess the influence of intracerebroventricular obestatin on colonic motility and secretion in conscious rats. Peptides 31: 1113–1117.
35. Chen CY, Tsai CY, Lee WJ, Liaw WJ, Chiang CH, Ho ST et al. (2012b). Intracerebroventricular O-n-octanoylated ghrelin and its splice variant-induced feeding is blocked by insulin, independent of obestatin or CRF receptor, in satiated rats. Nutrition 28: 812–820.
36. Cui AD, Gai NN, Zhang XH, Jia KZ, Yang YL, Song ZJ (2012). Decreased serum obestatin consequent upon TRIB3 Q84R polymorphism exacerbates carotid atherosclerosis in subjects with metabolic syndrome. Diabetol Metab Syndr 4: 52.
37. Dardennes RM, Zizzari P, Tolle V, Foulon C, Kipman A, Romo L et al. (2007). Family trios analysis of common polymorphisms in the obestatin/ghrelin, BDNF and AGRP genes in patients with anorexia nervosa: association with subtype, body-mass index, severity and age of onset. Psychoneuroendocrinology 32: 106–113.
38. Depoortere I, Thijs T, Moechars D, De Smet B, Ver Donck L, Peeters TL (2008). Effect of peripheral obestatin on food intake and gastric emptying in ghrelin-knockout mice. Br J Pharmacol 153: 1550–1557.
39. De Smet B, Thijs T, Peeters TL, Depoortere I (2007). Effect of peripheral obestatin on gastric emptying and intestinal contractility in rodents. Neurogastroenterol Motil 19: 211–217.
40. De Spiegeleer B, Van Dorpe S, Vergote V, Wynendaele E, Pauwels E, Van De Wiele C et al. (2012). In vitro metabolic stability of iodinated obestatin peptides. Peptides 33: 231–237.
41. Donath MY, Halban PA (2004). Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. Diabetologia 47: 581–589.
42. Dun SL, Brailoiu GC, Brailoiu E, Yang J, Chang JK, Dun NJ (2006). Distribution and biological activity of obestatin in the rat. J Endocrinol 191: 481–489.
43. Egido EM, Hernández R, Marco J, Silvestre RA (2009). Effect of obestatin on insulin, glucagon and somatostatin secretion in the perfused rat pancreas. Regul Pept 152: 61–66.
44. Emami A, Nazem R, Hedayati M (2014). Is association between thyroid hormones and gut peptides, ghrelin and obestatin, able to suggest new regulatory relation between the HPT axis and gut? Regul Pept 189: 17–21.
45. Favaro E, Granata R, Miceli I, Baragli A, Settanni F, Cavallo Perin P et al. (2012). The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways. Diabetologia 55: 1058–1070.
46. Fontenot E, DeVente JE, Seidel ER (2007). Obestatin and ghrelin in obese and in pregnant women. Peptides 28: 1937–1944.
47. Fujimiya M, Asakawa A, Ataka K, Kato I, Inui A (2008). Different effects of ghrelin, des-acyl ghrelin and obestatin on gastroduodenal motility in conscious rats. World J Gastroenterol 14: 6318–6326.
48. Fujimiya M, Ataka K, Asakawa A, Chen CY, Kato I, Inui A (2012). Regulation of gastroduodenal motility: acyl ghrelin, des-acyl ghrelin and obestatin and hypothalamic peptides. Digestion 85: 90–94.
49. Galic S, Oakhill JS, Steinberg GR (2010). Adipose tissue as an endocrine organ. Mol Cell Endocrinol 316: 129–139.
50. Gao XY, Kuang HY, Liu XM, Ma ZB (2010). Decreased gastric body mucosa obestatin expression in overweight and obese patients. Peptides 31: 291–296.
51. Gao XY, Kuang HY, Liu XM, Ma ZB (2014). Decreased gastric body mucosa obestatin expression in abdominal obesity patients with normal body mass index. Biomed Environ Sci 27: 385–387.
52. Gao XY, Kuang HY, Liu XM, Wang XY, Pan YH, Ma XX (2008). Decreased obestatin in plasma in metabolically obese, normal-weight men with normal glucose tolerance. Diabetes Res Clin Pract 79: e5–e6.
53. Germain N, Galusca B, Grouselle D, Frere D, Billard S, Epelbaum J et al. (2010). Ghrelin and obestatin circadian levels differentiate bingeing–purging from restrictive anorexia nervosa. J Clin Endocrinol Metab 95: 3057–3062.
54. Germain N, Galusca B, Grouselle D, Frere D, Tolle V, Zizzari P et al. (2009). Ghrelin/obestatin ratio in two populations with low bodyweight: constitutional thinness and anorexia nervosa. Psychoneuroendocrinology 34: 413–419.
55. Ghanbari-Niaki A (2010). Plasma obestatin, estradiol, and liver ATP concentrations in response to endurance exercise training at different durations in male rats. Int J Endocrinol Metab 8: 147–152.
56. Goldsmith SR, Gheorghiade M (2005). Vasopressin antagonism in heart failure. J Am Coll Cardiol 46: 1785–1791.
57. Gourcerol G, Coskun T, Craft LS, Mayer JP, Heiman ML, Wang L et al. (2007a). Preproghrelin-derived peptide, obestatin, fails to influence food intake in lean or obese rodents. Obesity (Silver Spring) 15: 2643–2652.
58. Gourcerol G, Million M, Adelson DW, Wang Y, Wang L, Rivier J et al. (2006). Lack of interaction between peripheral injection of CCK and obestatin in the regulation of gastric satiety signaling in rodents. Peptides 27: 2811–2819.
59. Gourcerol G, St-Pierre DH, Tache Y (2007b). Lack of obestatin effects on food intake: should obestatin be renamed ghrelin-associated peptide (GAP)? Regul Pept 141: 1–7.
60. Gourcerol G, Taché Y (2007). Obestatin – a ghrelin-associated peptide that does not hold its promise to suppress food intake and motility. Neurogastroenterol Motil 19: 161–165.
61. Grala TM, Kay JK, Walker CG, Sheahan AJ, Littlejohn MD, Lucy MC et al. (2010). Expression analysis of key somatotropic axis and liporegulatory genes in ghrelin- and obestatin-infused dairy cows. Domest Anim Endocrinol 39: 76–83.
62. Granata R, Baragli A, Settanni F, Scarlatti F, Ghigo E (2010a). Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. J Mol Endocrinol 45: 107–118.
63. Granata R, Gallo D, Luque RM, Baragli A, Scarlatti F, Grande C et al. (2012). Obestatin regulates adipocyte function and protects against diet-induced insulin resistance and inflammation. FASEB J 26: 3393–3411.
64. Granata R, Settanni F, Gallo D, Trovato L, Biancone L, Cantaluppi V et al. (2008). Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes 57: 967–979.
65. Granata R, Volante M, Settanni F, Gauna C, Ghé C, Annunziata M et al. (2010b). Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. J Mol Endocrinol 45: 9–17.
66. Green BD, Irwin N, Flatt PR (2007). Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice. Peptides 28: 981–987.
67. Grönberg M, Tsolakis AV, Holmbäck U, Stridsberg M, Grimelius L, Janson ET (2013). Ghrelin and obestatin in human neuroendocrine tumors: expression and effect on obestatin levels after food intake. Neuroendocrinology 97: 291–299.
68. Grönberg M, Tsolakis AV, Magnusson L, Janson ET, Saras J (2008). Distribution of obestatin and ghrelin in human tissues: immunoreactive cells in the gastrointestinal tract, pancreas, and mammary glands. J Histochem Cytochem 56: 793–801.
69. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV et al. (1999). Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100: 1134–1146.
70. Gu PY, Kang DM, Wang WD, Chen Y, Zhao ZH, Zheng H et al. (2013). Relevance of plasma obestatin and early arteriosclerosis in patients with type 2 diabetes mellitus. J Diabetes Res 2013: 563919.
71. Guilherme A, Virbasius JV, Puri V, Czech MP (2010). Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9: 367–377.
72. Guo ZF, Ren AJ, Zheng X, Qin YW, Cheng F, Zhang J et al. (2008). Different responses of circulating ghrelin, obestatin levels to fasting, re-feeding and different food compositions, and their local expressions in rats. Peptides 29: 1247–1254.
73. Guo Z, Zheng X, Qin Y, Hu J, Chen S, Zhang Z (2007). Circulating preprandial ghrelin to obestatin ratio is increased in human obesity. J Clin Endocrinol Metab 92: 1875–1880.
74. Gurgul E, Ruchala M, Kosowicz J, Zamyslowska H, Wrotkowska E, Moczko J et al. (2012). Ghrelin and obestatin in thyroid dysfunction. Endokrynol Pol 63: 456–462.
75. Gurriarán-Rodríguez U, Al-Massadi O, Crujeiras AB, Mosteiro CS, Amil-Diz M, Beiroa D et al. (2011a). Preproghrelin expression is a key target for insulin action on adipogenesis. J Endocrinol 210: R1–R7.
76. Gurriarán-Rodríguez U, Al-Massadi O, Roca-Rivada A, Crujeiras AB, Gallego R, Pardo M et al. (2011b). Obestatin as a regulator of adipocyte metabolism and adipogenesis. J Cell Mol Med 15: 1927–1940.
77. Gurriarán-Rodríguez U, Santos-Zas I, González-Sánchez J, Beiroa D, Moresi V, Mosteiro CS et al. (2015). Action of obestatin in skeletal muscle repair: stem cell expansion, muscle growth, and microenvironment remodeling. Mol Ther 6: 1003–1021.
78. Gutierrez-Grobe Y, Villalobos-Blasquez I, Sánchez-Lara K, Villa AR, Ponciano-Rodríguez G, Ramos MH et al. (2010). High ghrelin and obestatin levels and low risk of developing fatty liver. Ann Hepatol 9: 52–57.
79. Haider DG, Schindler K, Prager G, Bohdjalian A, Luger A, Wolzt M et al. (2007). Serum retinol-binding protein 4 is reduced after weight loss in morbidly obese subjects. J Clin Endocrinol Metab 92: 1168–1171.
80. Harada T, Nakahara T, Yasuhara D, Kojima S, Sagiyama K, Amitani H et al. (2008). Obestatin, acyl ghrelin, and des-acyl ghrelin responses to an oral glucose tolerance test in the restricting type of anorexia nervosa. Biol Psychiatry 63: 245–247.
81. Harsch IA, Koebnick C, Tasi AM, Hahn EG, Konturek PC (2009). Ghrelin and obestatin levels in type 2 diabetic patients with and without delayed gastric emptying. Dig Dis Sci 54: 2161–2166.
82. Hassouna R, Zizzari P, Viltart O, Yang SK, Gardette R, Videau C et al. (2012). A natural variant of obestatin, Q90L, inhibits ghrelin's action on food intake and GH secretion and targets NPY and GHRH neurons in mice. PLoS One 7: e51135.
83. Hedayati M, Saghebjoo M, Ghanbari-Niaki A (2012). Effects of circuit resistance training intensity on the plasma ghrelin to obestatin ratios in healthy young women. Int J Endocrinol Metab 10: 475–479.
84. Holst B, Egerod KL, Schild E, Vickers SP, Cheetham S, Gerlach LO et al. (2007). GPR39 signaling is stimulated by zinc ions but not by obestatin. Endocrinology 148: 13–20.
85. Hotamisligil GS (2006). Inflammation and metabolic disorders. Nature 444: 860–867.
86. Huang J, Zhang Y, Yu S, Gan X, Su Y, Yuan J et al. (2012). Circulating obestatin concentration is lowered by insulin in rats. Exp Clin Endocrinol Diabetes 120: 56–58.
87. Huda MS, Durham BH, Wong SP, Deepak D, Kerrigan D, McCulloch P et al. (2008). Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. Int J Obes (Lond) 32: 129–135.
88. Huda M, Mani H, Durham B, Dovey T, Halford J, Aditya S et al. (2007). Changes in circulating plasma ghrelin and obestatin in narcolepsy–cataplexy. Sleep 30 (Suppl): A218–A219.
89. Iglesias MJ, Salgado A, Piñeiro R, Rodiño BK, Otero MF, Grigorian L et al. (2007). Lack of effect of the ghrelin gene-derived peptide obestatin on cardiomyocyte viability and metabolism. J Endocrinol Invest 30: 470–476.
90. International Diabetes Federation (2015). IDF Diabetes Atlas Seventh Edition http://www.idf.org/diabetesatlas.
91. Jung JY, Jeong JB, Kim JW, Kim SH, Koh SJ, Kim BG et al. (2015). Circulating ghrelin levels and obestatin/ghrelin ratio as a marker of activity in ulcerative colitis. Intest Res 13: 68–73.
92. Kanat BH, Ayten R, Aydin S, Girgin M, Çetinkaya Z, Ilhan YS et al. (2014). Significance of appetite hormone ghrelin and obestatin levels in the assessment of the severity of acute pancreatitis. Turkish J Gastroenterol 25: 309–313.
93. Kapica M, Zabielska M, Puzio I, Jankowska A, Kato I, Kuwahara A et al. (2007). Obestatin stimulated the secretion of pancreatic juice enzymes through a vagal pathway in anaesthetized rats – preliminary results. J Physiol Pharmacol 58: 123–130.
94. Kellokoski E, Kunnari A, Jokela M, Makela S, Kesaniemi YA, Horkko S (2009). Ghrelin and obestatin modulate early atherogenic processes on cells: enhancement of monocyte adhesion and oxidized low-density lipoprotein binding. Metabolism 58: 1572–1580.
95. Khirazova EE, Bayzhumanov AA, Motorykina ES, Devyatov AA, Maslova MV, Graf AV et al. (2015). Antioxidant defense system after single and chronic administration of obestatin and its fragment (1–4) to normal and overweight male rats. Bull Exp Biol Med 159: 38–40.
96. Khirazova EE, Maslova MV, Motorykina ES, Frid DA, Graf AV, Maklakova AS et al. (2013). Effects of single intranasal administration of obestatin fragments on the body weight and feeding and drinking behaviors. Dokl Biol Sci 453: 336–337.
97. Kiewiet RM, Gauna C, van Aken MO, van de Zande B, van der Lely AJ (2008). Bolus administration of obestatin does not change glucose and insulin levels neither in the systemic nor in the portal circulation of the rat. Peptides 29: 2144–2149.
98. Kobelt P, Wisser AS, Stengel A, Goebel M, Bannert N, Gourcerol G et al. (2008). Peripheral obestatin has no effect on feeding behavior and brain Fos expression in rodents. Peptides 29: 1018–1027.
99. Koca SS, Ozgen M, Aydin S, Dag S, Evren B, Isik A (2008). Ghrelin and obestatin levels in rheumatoid arthritis. Inflammation 31: 329–335.
100. Kong XJ, Gao L, Peng H, Shi X (2010). Effects of electro-acupuncture on expression of obestatin in hypothalamus of rats with simple obesity. Zhong Xi Yi Jie He Xue Bao 8: 480–485.
101. Kosowicz J, Baumann-Antczak A, Ruchała M, Gryczyñska M, Gurgul E, Sowiñski J (2011). Thyroid hormones affect plasma ghrelin and obestatin levels. Horm Metab Res 43: 121–125.
102. Ku JM, Andrews ZB, Barsby T, Reichenbach A, Lemus MB, Drummond GR et al. (2015). Ghrelin-related peptides exert protective effects in the cerebral circulation of male mice through a nonclassical ghrelin receptor(s). Endocrinology 156: 280–290.
103. Kukuvitis A, Froudarakis M, Tryfon S, Tzouvelekis A, Saroglou M, Karkavitsas N et al. (2010). Acute effect of smoking on plasma obestatin levels. Tob Induc Dis 8: 2.
104. Lauwers E, Landuyt B, Arckens L, Schoofs L, Luyten W (2006). Obestatin does not activate orphan G protein-coupled receptor GPR39. Biochem Biophys Res Commun 351: 21–25.
105. Lee WJ, Chen CY, Ser KH, Chong K, Chen SC, Lee PC et al. (2013). Differential influences of gastric bypass and sleeve gastrectomy on plasma nesfatin-1 and obestatin levels in patients with type 2 diabetes mellitus. Curr Pharm Des 19: 5830–5835.
106. Lei Y, Liang Y, Chen Y, Liu X, Liao X, Luo F (2014). Increased circulating obestatin in patients with chronic obstructive pulmonary disease. Multidiscip Respir Med 9: 5.
107. Li ZF, Guo ZF, Cao J, Hu JQ, Zhao XX, Xu RL et al. (2010a). Plasma ghrelin and obestatin levels are increased in spontaneously hypertensive rats. Peptides 31: 297–300.
108. Li ZF, Guo ZF, Yang SG, Zheng X, Cao J, Qin YW (2010b). Circulating ghrelin and ghrelin to obestatin ratio are low in patients with untreated mild-to-moderate hypertension. Regul Pept 165: 206–209.
109. Li ZF, Song SW, Qin YW, Zhang JL, Zhao XX, Zhang BL et al. (2009). Bolus intravenous injection of obestatin does not change blood pressure level of spontaneously hypertensive rat. Peptides 30: 1928–1930.
110. Li ZF, Zhou DX, Pan WZ, Zhang L, Ge JB (2013). Circulating ghrelin was negatively correlated with pulmonary arterial pressure in atrial septal defect patients. Chin Med J (Engl) 126: 3936–3939.
111. Lippl F, Erdmann J, Lichter N, Tholl S, Wagenpfell S, Adam O et al. (2008). Relation of plasma obestatin levels to BMI, gender, age and insulin. Horm Metab Res 40: 806–812.
112. Liu W, Yue H, Zhang J, Pu J, Yu Q (2014). Effects of plasma ghrelin, obestatin, and ghrelin/obestatin ratio on blood pressure circadian rhythms in patients with obstructive sleep apnea syndrome. Chin Med J (Engl) 127: 850–855.
113. Mafra D, Guebre-Egziabher F, Cleaud C, Arkouche W, Mialon A, Drai J et al. (2010). Obestatin and ghrelin interplay in hemodialysis patients. Nutrition 26: 1100–1104.
114. Matuszyk A, Ceranowicz P, Warzecha Z, Cieszkowski J, Bonior J, Jaworek J et al. (2015). Obestatin accelerates the healing of acetic acid-induced colitis in rats. Oxid Med Cell Longev 2016.2834386
115. Miegueu P, St Pierre D, Broglio F, Cianflone K (2011). Effect of desacyl ghrelin, obestatin and related peptides on triglyceride storage, metabolism and GHSR signaling in 3T3-L1 adipocytes. J Cell Biochem 112: 704–714.
116. Mizutani M, Atsuchi K, Asakawa A, Matsuda N, Fujimura M, Inui A et al. (2009). Localization of acyl ghrelin- and des-acyl ghrelin-immunoreactive cells in the rat stomach and their responses to intragastric pH. Am J Physiol Gastrointest Liver Physiol 297: G974–G980.
117. Moechars D, Depoortere I, Moreaux B, de Smet B, Goris I, Hoskens L et al. (2006). Altered gastrointestinal and metabolic function in the GPR39-obestatin receptor-knockout mouse. Gastroenterology 131: 1131–1141.
118. Mondal MS, Toshinai K, Ueno H, Koshinaka K, Nakazato M (2008). Characterization of obestatin in rat and human stomach and plasma, and its lack of acute effect on feeding behavior in rodents. J Endocrinol 198: 339–346.
119. Monteleone P, Serritella C, Martiadis V, Maj M (2008a). Deranged secretion of ghrelin and obestatin in the cephalic phase of vagal stimulation in women with anorexia nervosa. Biol Psychiatry 64: 1005–1008.
120. Monteleone P, Serritella C, Martiadis V, Scognamiglio P, Maj M (2008b). Plasma obestatin, ghrelin, and ghrelin/obestatin ratio are increased in underweight patients with anorexia nervosa but not in symptomatic patients with bulimia nervosa. J Clin Endocrinol Metab 93: 4418–4421.
121. Mora M, Granada ML, Roca M, Palomera E, Puig R, Serra-Prat M et al. (2013). Obestatin does not modify weight and nutritional behaviour but is associated with metabolic syndrome in old women. Clin Endocrinol (Oxf) 78: 882–890.
122. Moretti E, Collodel G, Iacoponi F, Geminiani M, Pascarelli NA, Campagna S et al. (2011). Detection of obestatin in seminal plasma and its relationship with ghrelin and semen parameters. Fertil Steril 95: 2303–2309.
123. Motorykina ES, Khirazova EE, Maslova MV, Maklakova AS, Graf AV, Bayzhymanov AA et al. (2015). Changes in feeding and drinking motivations and glucose content in male rats after single or chronic administration of obestatin or its fragment (1–4). Dokl Biol Sci 460: 1–4.
124. Nagaraj S, Peddha MS, Manjappara UV (2008). Fragments of obestatin as modulators of feed intake, circulating lipids, and stored fat. Biochem Biophys Res Commun 366: 731–737.
125. Nagaraj S, Peddha MS, Manjappara UV (2009). Fragment analogs as better mimics of obestatin. Regul Pept 158: 143–148.
126. Nagaraj S, Raghavan AV, Rao SN, Manjappara UV (2014). Obestatin and Nt8U influence glycerolipid metabolism and PPAR gamma signaling in mice. Int J Biochem Cell Biol 53: 414–422.
127. Nakahara T, Harada T, Yasuhara D, Shimada N, Amitani H, Sakoguchi T et al. (2008). Plasma obestatin concentrations are negatively correlated with body mass index, insulin resistance index, and plasma leptin concentrations in obesity and anorexia nervosa. Biol Psychiatry 64: 252–255.
128. Nogueiras R, Pfluger P, Tovar S, Arnold M, Mitchell S, Morris A et al. (2007). Effects of obestatin on energy balance and growth hormone secretion in rodents. Endocrinology 148: 21–26.
129. Ozbay Y, Aydin S, Dagli AF, Akbulut M, Dagli N, Kilic N et al. (2008). Obestatin is present in saliva: alterations in obestatin and ghrelin levels of saliva and serum in ischemic heart disease. BMB Rep 41: 55–61.
130. Pamukcu O, Kumral ZN, Ercan F, Yegen BÇ, Ertem D (2013). Anti-inflammatory effect of obestatin and ghrelin in dextran sulfate sodium–induced colitis in rats. J Pediatr Gastroenterol Nutr 57: 211–218.
131. Pattnaik P (2005). Surface plasmon resonance: applications in understanding receptor–ligand interaction. Appl Biochem Biotechnol 126: 79–92.
132. Popovics P, Stewart AJ (2011). GPR39: a Zn2+-activated G protein-coupled receptor that regulates pancreatic, gastrointestinal and neuronal functions. Cell Mol Life Sci 68: 85–95.
133. Prodam F, Cadario F, Bellone S, Trovato L, Moia S, Pozzi E et al. (2014). Obestatin levels are associated with C-peptide and anti-insulin antibodies at the onset whereas unacylated and acylated ghrelin levels are not predictive of long-term metabolic control in children with type 1 diabetes. J Clin Endocrinol Metab 99: E599–E607.
134. Pruszynska-Oszmalek E, Szczepankiewicz D, Hertig I, Skrzypski M, Sassek M, Kaczmarek P et al. (2013). Obestatin inhibits lipogenesis and glucose uptake in isolated primary rat adipocytes. J Biol Regul Homeost Agents 27: 23–33.
135. Qader SS, Håkanson R, Rehfeld JF, Lundquist I, Salehi A (2008). Proghrelin-derived peptides influence the secretion of insulin, glucagon, pancreatic polypeptide and somatostatin: A study on isolated islets from mouse and rat pancreas. Regul Pept 146: 230–237.
136. Qi X, Li L, Yang G, Liu J, Li K, Tang Y et al. (2007). Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus. Clin Endocrinol (Oxf) 66: 593–597.
137. Reinehr T, De ousa G, Roth CL (2008). Obestatin and ghrelin levels in obese children and adolescents before and after reduction of overweight. Clin Endocrinol (Oxf) 68: 304–310.
138. Ren A, Guo Z, Wang YK, Wang LG, Wang W, Lin L et al. (2008). Inhibitory effect of obestatin on glucose-induced insulin secretion in rats. Biochem Biophys Res Commun 369: 969–972.
139. Ren AJ, He Q, Shi JS, Guo ZF, Zheng X, Lin L et al. (2009). Association of obestatin with blood pressure in the third trimesters of pregnancy. Peptides 30: 1742–1745.
140. Ren G, He Z, Cong P, Chen H, Guo Y, Yu J et al. (2013a). Peripheral administration of TAT-obestatin can influence the expression of liporegulatory genes but fails to affect food intake in mice. Peptides 42: 8–14.
141. Ren G, He Z, Cong P, Yu J, Qin Y, Chen Y et al. (2013b). Effect of TAT-obestatin on proliferation, differentiation, apoptosis and lipolysis in 3 T3-L1 preadipocytes. J Pept Sci 19: 684–691.
142. Robinson E, Cassidy RS, Tate M, Zhao Y, Lockhart S, Calderwood D et al. (2015). Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix. Basic Res Cardiol 110: 20.
143. Roth C, Reinehr T, Schernthaner G, Kopp H, Kriwanek S, Schernthaner G (2009). Ghrelin and obestatin levels in severely obese women before and after weight loss after Roux-en-Y gastric bypass surgery. Obes Surg 19: 29–35.
144. Saliakelis E, Iakovou I, Varlamis G, Karatzas N, Garstioni S, Fotoulaki M (2014). Serum obestatin, ghrelin, and ghrelin/obestatin ratio are increased in children with symptoms suggestive of delayed gastric emptying of unclear etiology. Eur J Nucl Med Mol Imaging 41: S579–S580.
145. Samson WK, White MM, Price C, Ferguson AV (2007). Obestatin acts in brain to inhibit thirst. Am J Physiol Regul Integr Comp Physiol 292: R637–R643.
146. Samson WK, Yosten GL, Chang JK, Ferguson AV, White MM (2008). Obestatin inhibits vasopressin secretion: evidence for a physiological action in the control of fluid homeostasis. J Endocrinol 196: 559–564.
147. Savino F, Benetti S, Lupica MM, Petrucci E, Palumeri E, Cordero di Montezemolo L (2012). Ghrelin and obestatin in infants, lactating mothers and breast milk. Horm Res Paediatr 78: 297–303.
148. Sazdova IV, Ilieva BM, Minkov IB, Schubert R, Gagov HS (2009). Obestatin as contractile mediator of excised frog heart. Cent Eur J Biol 4: 327–334.
149. Schinzari F, Iantorno M, Campia U, Mores N, Rovella V, Tesauro M et al. (2015). Vasodilator responses and endothelin-dependant vasoconstriction in metabolically healthy obesity and the metabolic syndrome. Am J Physiol Endocrinol Metab 309: E787–E792.
150. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B et al. (2013). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369: 1317–1326.
151. Scrima M, Campiglia P, Esposito C, Gomez-Monterrey I, Novellino E, D'Ursi AM (2007). Obestatin conformational features: a strategy to unveil obestatin's biological role? Biochem Biophys Res Commun 363: 500–505.
152. Sedlácková D, Dostálová I, Hainer V, Beranová L, Kvasnicková H, Hill M et al. (2008). Simultaneous decrease of plasma obestatin and ghrelin levels after a high-carbohydrate breakfast in healthy women. Physiol Res 57 (Suppl 1): S29–S37.
153. Sedlackova D, Kopeckova J, Papezova H, Hainer V, Kvasnickova H, Hill M et al. (2012). Comparison of a high-carbohydrate and high-protein breakfast effect on plasma ghrelin, obestatin, NPY and PYY levels in women with anorexia and bulimia nervosa. Nutr Metab (Lond) 9: 52.
154. Sedlácková D, Kopečková J, Papežová H, Vybíral S, Kvasničková H, Hill M et al. (2011). Changes of plasma obestatin, ghrelin and NPY in anorexia and bulimia nervosa patients before and after a high-carbohydrate breakfast. Physiol Res 60: 165–173.
155. Seim I, Walpole C, Amorim L, Josh P, Herington A, Chopin L (2011). The expanding roles of the ghrelin-gene derived peptide obestatin in health and disease. Mol Cell Endocrinol 340: 111–117.
156. Şen LS, Karakoyun B, Yeğen C, Akkiprik M, Yüksel M, Ercan F et al. (2015). Treatment with either obestatin or ghrelin attenuates mesenteric ischemia–reperfusion-induced oxidative injury of the ileum and the remote organ lung. Peptides 71: 8–19.
157. Seoane LM, Al-Massadi O, Pazos Y, Pagotto U, Casanueva FF (2006). Central obestatin administration does not modify either spontaneous or ghrelin-induced food intake in rats. J Endocrinol Invest 29: RC13–RC15.
158. Shao L, Zhao YT, Teng LL, Li MZ, Jiang H (2014). Circulating obestatin levels correlate with fasting insulin and HOMA-IR but not with hypertension in elderly men. Cell Biochem Biophys 69: 89–92.
159. Shen C, Yu T, Tang ZH, Wu KM (2013). Changes in ghrelin and obestatin levels before and after a meal in children with simple obesity and anorexia. Horm Res Paediatr 79: 341–346.
160. Shi JB, Guo ZF, Zheng X, Wang ZB, Ma YJ (2012). Circulating obestatin is increased in patients with cardiorenal syndrome and positively correlated with vasopressin. Peptides 38: 377–380.
161. Sibilia V, Bresciani E, Lattuada N, Rapetti D, Locatelli V, De Luca V et al. (2006). Intracerebroventricular acute and chronic administration of obestatin minimally affect food intake but not weight gain in the rat. J Endocrinol Invest 29: RC31–RC34.
162. Siejka A, Jankiewicz-Wika J, Kołomecki K, Cywiński J, Piestrzeniewicz K, Swiętosławski J et al. (2013). Long-term impact of vertical banded gastroplasty (VBG) on plasma concentration of leptin, soluble leptin receptor, ghrelin, omentin-1, obestatin, and retinol binding protein 4 (RBP4) in patients with severe obesity. Cytokine 64: 490–493.
163. Słupecka M, Pierzynowski SG, Kuwahara A, Kato I, Woliński J (2014). Age-dependent effect of obestatin on intestinal contractility in Wistar rats. Gen Comp Endocrinol 208: 109–115.
164. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl. Acids Res. 44: D1054–D1068.
165. St-Pierre DH, Settanni F, Olivetti I, Gramaglia E, Tomelini M, Granata R et al. (2010). Circulating obestatin levels in normal and type 2 diabetic subjects. J Endocrinol Invest 33: 211–214.
166. Subasinghage AP, Green BD, Flatt PR, Irwin N, Hewage CM (2010). Metabolic and structural properties of human obestatin {1–23} and two fragment peptides. Peptides 31: 1697–1705.
167. Tang S, Dong X, Zhang W (2014). Obestatin changes proliferation, differentiation and apoptosis of porcine preadipocytes. Ann Endocrinol (Paris) 75: 1–9.
168. Taskin MI, Bulbul E, Adali E, Hismiogulları AA, Inceboz U (2015). Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 189: 19–23.
169. Taskin E, Atli B, Kiliç M, Sari Y, Aydin S (2014). Serum, urine, and saliva levels of ghrelin and obestatin pre-and post-treatment in pediatric epilepsy. Pediatr Neurol 51: 365–369.
170. Tate M, Chong A, Robinson E, Green BD, Grieve DJ (2015). Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol 172: 721–736.
171. Tate M, Robinson E, Green BD, McDermott BJ, Grieve DJ (2016). Exendin-4 attenuates adverse cardiac remodelling in streptozotocin-induced diabetes via specific actions on infiltrating macrophages. Basic Res Cardiol 111: 1.
172. Tokudome T, Kishimoto I, Myazato M, Kangawa K (2014). Ghrelin and the cardiovascular system. Cardiovasc Issues Endocrinol 43: 125–133.
173. Tremblay F, Perreault M, Klaman LD, Tobin JF, Smith E, Gimeno RE (2007). Normal food intake and body weight in mice lacking the G protein-coupled receptor GPR39. Endocrinology 148: 501–506.
174. Uehara M, Yasuhara D, Nakahara T, Harada T, Ushikai M, Asakawa A et al. (2011). Increase in energy intake leads to a decrease in obestatin in restricting-type of anorexia nervosa. Exp Clin Endocrinol Diabetes 119: 536–539.
175. Unniappan S, Speck M, Kieffer TJ (2008). Metabolic effects of chronic obestatin infusion in rats. Peptides 29: 1354–1361.
176. Van Dijck A, Annemie VD, Van Dam D, Debby VD, Vergote V, Valentijn V et al. (2009). Central administration of obestatin fails to show inhibitory effects on food and water intake in mice. Regul Pept 156: 77–82.
177. Vergote V, Van Dorpe S, Peremans K, Burvenich C, De Spiegeleer B (2008). In vitro metabolic stability of obestatin: kinetics and identification of cleavage products. Peptides 29: 1740–1748.
178. Vicennati V, Genghini S, De Iasio R, Pasqui F, Pagotto U, Pasquali R (2007). Circulating obestatin levels and the ghrelin/obestatin ratio in obese women. Eur J Endocrinol 157: 295–301.
179. Wali P, King J, He Z, Tonb D, Horvath K (2014). Ghrelin and obestatin levels in children with failure to thrive and obesity. J Pediatr Gastroenterol Nutr 58: 376–381.
180. Wang WM, Li SM, Du FM, Zhu ZC, Zhang JC, Li YX (2014). Ghrelin and obestatin levels in hypertensive obese patients. J Int Med Res 42: 1202–1208.
181. Wasilewski MA, Myers VD, Recchia FA, Feldman AM, Tilley DG (2015). Arginine vasopressin receptor signaling and functional outcomes in heart failure. Cell Signal 28: 224–233.
182. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL et al. (2013). Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369: 1327–1335.
183. Wojciechowicz T, Skrzypski M, Kołodziejski PA, Szczepankiewicz D, Pruszyńska-Oszmałek E, Kaczmarek P et al. (2015). Obestatin stimulates differentiation and regulates lipolysis and leptin secretion in rat preadipocytes. Mol Med Rep 12: 8169–8175.
184. Wu W, Fan X, Yu Y, Wang Y (2015). Maternal serum ratio of ghrelin to obestatin decreased in preeclampsia. Pregnancy Hypertens 5: 263–266.
185. Xin X, Ren AJ, Zheng X, Qin YW, Zhao XX, Yuan WJ et al. (2009). Disturbance of circulating ghrelin and obestatin in chronic heart failure patients especially in those with cachexia. Peptides 30: 2281–2285.
186. Xu L, Depoortere I, Tomasetto C, Zandecki M, Tang M, Timmermans JP et al. (2005). Evidence for the presence of motilin, ghrelin, and the motilin and ghrelin receptor in neurons of the myenteric plexus. Regul Pept 124: 119–125.
187. Yamamoto D, Ikeshita N, Daito R, Herningtyas EH, Toda K, Takahashi K et al. (2007). Neither intravenous nor intracerebroventricular administration of obestatin affects the secretion of GH, PRL, TSH and ACTH in rats. Regul Pept 138: 141–144.
188. Yuan X, Cai W, Liang XF, Su H, Yuan Y, Li A et al. (2015). Obestatin partially suppresses ghrelin stimulation of appetite in ‘high-responders’ grass carp, Ctenopharyngodon idellus. Comp Biochem Physiol A Mol Integr Physiol 184: 144–149.
189. Zamrazilová H, Hainer V, Ková DS, Papežová H, Kunešová M, Bellisle F et al. (2008). Plasma obestatin levels in normal weight, obese and anorectic women. Physiol Res 57: S49–S55.
190. Zhang JV, Jahr H, Luo CW, Klein C, Van Kolen K, Ver Donck L et al. (2008a). Obestatin induction of early-response gene expression in gastrointestinal and adipose tissues and the mediatory role of G protein-coupled receptor, GPR39. Mol Endocrinol 22: 1464–1475.
191. Zhang JV, Klein C, Ren PG, Kass S, Ver Donck L, Moechars D et al. (2007). Response to Comment on “Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake”. Science 315: 766.
192. Zhang JV, Ren P, Avsian-Kretchmer O (2005). Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 310: 996–999.
193. Zhang S, Zhai G, Zhang J, Zhou J, Chen C (2014). Ghrelin and obestatin plasma levels and ghrelin/obestatin prepropeptide gene polymorphisms in small for gestational age infants. J Int Med Res 42: 1232–1242.
194. Zhang W, Chai B, Li JY, Wang H, Mulholland MW (2008b). Effect of des-acyl ghrelin on adiposity and glucose metabolism. Endocrinology 149: 4710–4716.
195. Zhao CM, Furnes MW, Stenström B, Kulseng B, Chen D (2008). Characterization of obestatin- and ghrelin-producing cells in the gastrointestinal tract and pancreas of rats: an immunohistochemical and electron-microscopic study. Cell Tissue Res 331: 575–587.
196. Zizzari P, Longchamps R, Epelbaum J, Bluet-Pajot MT (2007). Obestatin partially affects ghrelin stimulation of food intake and growth hormone secretion in rodents. Endocrinology 148: 1648–1653.
197. Zou CC, Liang L, Wang CL, Fu JF, Zhao ZY (2009). The change in ghrelin and obestatin levels in obese children after weight reduction. Acta Paediatr Int J Paediatr 98: 159–165.